← All trials
NCT06446310
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 18, 2024
- Primary completion
- Feb 21, 2025
- Completion date
- Aug 3, 2025
- First posted
- Jun 6, 2024
- Last posted
- Jun 21, 2024
- Enrollment
- 194
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
- Peking UniversityOfficial
- Shandong Provincial HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.